These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 7586930)
1. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Barbhaiya RH; Shukla UA; Natarajan CS; Behr DA; Greene DS; Sainati SM Clin Pharmacol Ther; 1995 Oct; 58(4):390-8. PubMed ID: 7586930 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Marathe PH; Lee JS; Greene DS; Barbhaiya RH Br J Clin Pharmacol; 1996 Jan; 41(1):21-7. PubMed ID: 8824689 [TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Barbhaiya RH; Shukla UA; Greene DS Eur J Clin Pharmacol; 1995; 49(3):221-8. PubMed ID: 8665999 [TBL] [Abstract][Full Text] [Related]
4. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Kaul S; Shukla UA; Barbhaiya RH J Clin Pharmacol; 1995 Aug; 35(8):830-9. PubMed ID: 8522641 [TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Barbhaiya RH; Brady ME; Shukla UA; Greene DS Eur J Clin Pharmacol; 1995; 49(3):229-35. PubMed ID: 8666000 [TBL] [Abstract][Full Text] [Related]
6. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Barbhaiya RH; Shukla UA; Greene DS Br J Clin Pharmacol; 1995 Aug; 40(2):161-5. PubMed ID: 8562300 [TBL] [Abstract][Full Text] [Related]
7. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Barbhaiya RH; Buch AB; Greene DS J Clin Psychopharmacol; 1996 Feb; 16(1):19-25. PubMed ID: 8834414 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Mayol RF; Cole CA; Luke GM; Colson KL; Kerns EH Drug Metab Dispos; 1994; 22(2):304-11. PubMed ID: 8013286 [TBL] [Abstract][Full Text] [Related]
10. Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation. Barbhaiya RH; Shukla UA; Chaikin P; Greene DS; Marathe PH Eur J Clin Pharmacol; 1996; 50(1-2):101-7. PubMed ID: 8739819 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study. Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015 [TBL] [Abstract][Full Text] [Related]
12. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. Greene DS; Salazar DE; Dockens RC; Kroboth P; Barbhaiya RH J Clin Psychopharmacol; 1995 Dec; 15(6):399-408. PubMed ID: 8748428 [TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383 [TBL] [Abstract][Full Text] [Related]
14. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Ferry N; Bernard N; Cuisinaud G; Rougier P; Trepo C; Sassard J Fundam Clin Pharmacol; 1994; 8(5):463-73. PubMed ID: 7875642 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Zhao RK; Cheng G; Tang J; Song J; Peng WX Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103 [TBL] [Abstract][Full Text] [Related]
16. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. Barbhaiya RH; Shukla UA; Kroboth PD; Greene DS J Clin Psychopharmacol; 1995 Oct; 15(5):320-6. PubMed ID: 8830062 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog. Shukla UA; Kaul S; Marathe PH; Pittman KA; Barbhaiya RH Eur J Drug Metab Pharmacokinet; 1992; 17(4):309-18. PubMed ID: 1301361 [TBL] [Abstract][Full Text] [Related]
18. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects. Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Barbhaiya RH; Dandekar KA; Greene DS Drug Metab Dispos; 1996 Jan; 24(1):91-5. PubMed ID: 8825195 [TBL] [Abstract][Full Text] [Related]
20. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. Walsh AE; Cowen PJ J Clin Psychopharmacol; 1994 Aug; 14(4):268-73. PubMed ID: 7962683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]